R&D

Pipeline

Development of
Pharmabiotics(LBP)

New drug candidates Composition Indications TargetBioMe search Pre-clinical study Clinical trial Remarks
Microbiome-based biomarker LBP screening
HEM 20-01 Single strain Depression
US FDA phase 2 IND enabling in the second half of 2022
HEM 1036 Single strain Corolectal cancer syndrome (LARS)
Initiation of phase 2 study in Australia in the second half of 2022
Indication exploration process in progress Anticancer drug-induced severe diarrhea
Pilot study scheduled to be in 4Q of 2022
Cachexia
HEM 1670,
HEM 20-01
COPD
HEM 792, HEM 382, HEM 224
NAFLD
HEM 253, HEM 356, HEM 388
Childhood constipation
intestinal disease
FAP
IBD
Childhood autism
Mental disease
Pancreatic cancer
Cancer
Colon cancer
Solid cancer
Hematologic cancer

Development of
Probiotics

Product name Partner company Contract Product development Trial production Commercialization
BWI Immunity A**
Zeta Bio (B-active) C**
E. Faecium HAC233 L**
MyLAB by NUTRILITE A**
Customized lactic acid bacteria Our company’s new brand